The Regulatory Role of Exosomes in Leukemia and Their Clinical Significance

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2020 Aug 26

PMID 32840158

Citations 8

Authors

Wei Deng

Li Wang

Ming Pan

Jianping Zheng

Affiliations

Soon will be listed here.

Abstract

Recurrence is a primary cause of death in patients with leukemia. The interactions of tumor cells with the microenvironment and tumor stem cells hidden in bone marrow promote the recurrence and metastasis of leukemia to lymphoid tissue. Exosomes, membrane-coated nanovesicles secreted by living cells, perform biomaterial transfer and information exchange between cells. Exosomes contain various other biological components derived from parental cells, and they remotely regulate the function of target cells through body fluid flow. Recent studies revealed that exosomes participate in the development of leukemia and play important roles in its diagnosis and treatment by influencing cell proliferation and apoptosis, regulating bone marrow microenvironment, promoting angiogenesis, and inhibiting hematopoiesis. Exosomes are potential biomarkers and therapeutic targets for leukemia, and they can influence drug resistance. Leukemia-derived exosomes present leukemia-related antigens to target cells, promote the proliferation of leukemic cells, help these cells escape immunity, protect them from the cytotoxic effects of chemotherapeutics, and promote angiogenesis and tumor migration. Therefore, exosomes are closely related to the metastasis, treatment, and prognosis of leukemia, and they can be used to detect and monitor the progression of leukemia. This paper reviews the regulatory roles of exosomes in leukemia and their clinical significance.

Citing Articles

Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.

Mohseni A, Salehi F, Rostami S, Hadiloo K, Hashemi M, Baridjavadi Z Stem Cell Res Ther. 2025; 16(1):6.

PMID: 39773361 PMC: 11708188. DOI: 10.1186/s13287-024-04125-0.

The theragnostic advances of exosomes in managing leukaemia.

Ghosh S, Dey A, Chakrabarti A, Bhuniya T, Indu N, Hait A J Cell Mol Med. 2024; 28(23):e70052.

PMID: 39659020 PMC: 11632122. DOI: 10.1111/jcmm.70052.

Glycolysis and chemoresistance in acute myeloid leukemia.

Yang Y, Pu J, Yang Y Heliyon. 2024; 10(15):e35721.

PMID: 39170140 PMC: 11336864. DOI: 10.1016/j.heliyon.2024.e35721.

Utilizing exosomes as sparking clinical biomarkers and therapeutic response in acute myeloid leukemia.

Wang W, Wu X, Zheng J, Yin R, Li Y, Wu X Front Immunol. 2024; 14:1315453.

PMID: 38292478 PMC: 10824954. DOI: 10.3389/fimmu.2023.1315453.

Exosomes: A potential tool for immunotherapy of ovarian cancer.

Gong X, Chi H, Strohmer D, Teichmann A, Xia Z, Wang Q Front Immunol. 2023; 13:1089410.

PMID: 36741380 PMC: 9889675. DOI: 10.3389/fimmu.2022.1089410.

References

Khatun Z, Bhat A, Sharma S, Sharma A . Elucidating diversity of exosomes: biophysical and molecular characterization methods. Nanomedicine (Lond). 2016; 11(17):2359-77. DOI: 10.2217/nnm-2016-0192. View

de Carvalho I, Freitas R, Vargas F . Translating microRNAs into biomarkers: What is new for pediatric cancer?. Med Oncol. 2016; 33(5):49. DOI: 10.1007/s12032-016-0766-4. View

Fang Y, Garnier D, Lee T, DAsti E, Montermini L, Meehan B . PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells. Angiogenesis. 2015; 19(1):25-38. DOI: 10.1007/s10456-015-9486-1. View

Parikh S . Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J. 2018; 8(10):93. PMC: 6170426. DOI: 10.1038/s41408-018-0131-2. View

Paggetti J, Haderk F, Seiffert M, Janji B, Distler U, Ammerlaan W . Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 2015; 126(9):1106-17. PMC: 4560344. DOI: 10.1182/blood-2014-12-618025. View

Melo S, Luecke L, Kahlert C, Fernandez A, Gammon S, Kaye J . Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015; 523(7559):177-82. PMC: 4825698. DOI: 10.1038/nature14581. View

Mardani R, Jafari Najaf Abadi M, Motieian M, Taghizadeh-Boroujeni S, Bayat A, Farsinezhad A . MicroRNA in leukemia: Tumor suppressors and oncogenes with prognostic potential. J Cell Physiol. 2018; 234(6):8465-8486. DOI: 10.1002/jcp.27776. View

Bobrie A, Colombo M, Raposo G, Thery C . Exosome secretion: molecular mechanisms and roles in immune responses. Traffic. 2011; 12(12):1659-68. DOI: 10.1111/j.1600-0854.2011.01225.x. View

Taverna S, Giallombardo M, Pucci M, Flugy A, Manno M, Raccosta S . Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21. Oncotarget. 2015; 6(26):21918-33. PMC: 4673136. DOI: 10.18632/oncotarget.4204. View

10.

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

11.

Prieto D, Sotelo N, Seija N, Sernbo S, Abreu C, Duran R . S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression. Blood. 2017; 130(6):777-788. DOI: 10.1182/blood-2017-02-769851. View

12.

Juliusson G, Hough R . Leukemia. Prog Tumor Res. 2016; 43:87-100. DOI: 10.1159/000447076. View

13.

Ferrajoli A, Shanafelt T, Ivan C, Shimizu M, Rabe K, Nouraee N . Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013; 122(11):1891-9. PMC: 3779381. DOI: 10.1182/blood-2013-01-478222. View

14.

Kumar B, Garcia M, Weng L, Jung X, Murakami J, Hu X . Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia. 2017; 32(3):575-587. PMC: 5843902. DOI: 10.1038/leu.2017.259. View

15.

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

16.

Bellavia D, Raimondo S, Calabrese G, Forte S, Cristaldi M, Patinella A . Interleukin 3- receptor targeted exosomes inhibit and Chronic Myelogenous Leukemia cell growth. Theranostics. 2017; 7(5):1333-1345. PMC: 5399597. DOI: 10.7150/thno.17092. View

17.

Nabhan J, Hu R, Oh R, Cohen S, Lu Q . Formation and release of arrestin domain-containing protein 1-mediated microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 protein. Proc Natl Acad Sci U S A. 2012; 109(11):4146-51. PMC: 3306724. DOI: 10.1073/pnas.1200448109. View

18.

Guo S, Xu J, Estell A, Ivory C, Du D, Lin Y . Paper-based ITP technology: An application to specific cancer-derived exosome detection and analysis. Biosens Bioelectron. 2020; 164:112292. DOI: 10.1016/j.bios.2020.112292. View

19.

Bernardi S, Foroni C, Zanaglio C, Re F, Polverelli N, Turra A . Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia. Int J Mol Med. 2019; 44(6):2133-2144. PMC: 6844640. DOI: 10.3892/ijmm.2019.4372. View

20.

Raimondo S, Saieva L, Corrado C, Fontana S, Flugy A, Rizzo A . Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism. Cell Commun Signal. 2015; 13:8. PMC: 4320527. DOI: 10.1186/s12964-015-0086-x. View